Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery.

Conen D, Alonso-Coello P, Douketis J, Chan MTV, Kurz A, Sigamani A, Parlow JL, Wang CY, Villar JC, Srinathan SK, Tiboni M, Malaga G, Guyatt G, Sivakumaran S, Rodriguez Funes MV, Cruz P, Yang H, Dresser GK, Alvarez-Garcia J, Schricker T, Jones PM, Drummond LW, Balasubramanian K, Yusuf S, Devereaux PJ.

Eur Heart J. 2019 Jun 25. pii: ehz431. doi: 10.1093/eurheartj/ehz431. [Epub ahead of print]

PMID:
31237939
2.

Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1.

Medwid S, Li MMJ, Knauer MJ, Lin K, Mansell SE, Schmerk CL, Zhu C, Griffin KE, Yousif MD, Dresser GK, Schwarz UI, Kim RB, Tirona RG.

Drug Metab Dispos. 2019 Aug;47(8):832-842. doi: 10.1124/dmd.119.087619. Epub 2019 May 23.

PMID:
31123035
3.

Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation.

Sukumar S, Gulilat M, Linton B, Gryn SE, Dresser GK, Alfonsi JE, Schwarz UI, Kim RB, Schwartz JB.

J Am Geriatr Soc. 2019 Sep;67(9):1902-1906. doi: 10.1111/jgs.15982. Epub 2019 May 21.

PMID:
31112620
4.

Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.

Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NRC, Hiremath S, Roerecke M, Arcand J, Ruzicka M, Prasad GVR, Vallée M, Edwards C, Sivapalan P, Penner SB, Fournier A, Benoit G, Feber J, Dionne J, Magee LA, Logan AG, Côté AM, Rey E, Firoz T, Kuyper LM, Gabor JY, Townsend RR, Rabi DM, Daskalopoulou SS; Hypertension Canada.

Can J Cardiol. 2018 May;34(5):506-525. doi: 10.1016/j.cjca.2018.02.022. Epub 2018 Mar 1.

PMID:
29731013
5.

Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically.

Dresser GK, Urquhart BL, Proniuk J, Tieu A, Freeman DJ, Arnold JM, Bailey DG.

Pharmacol Res Perspect. 2017 Oct;5(5). doi: 10.1002/prp2.346.

6.

Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.

Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, Dresser GK, Henderson SL, Rose RV, Lizotte DJ, Teft WA, Schwarz UI, Tirona RG, Kim RB.

Can J Cardiol. 2017 Aug;33(8):1036-1043. doi: 10.1016/j.cjca.2017.04.008. Epub 2017 Apr 24.

PMID:
28754389
7.

Effects of Eplerenone on Resistance to Antihypertensive Medication in Patients with Primary or Secondary Hyperaldosteronism.

Spence JD, Bogiatzi C, Kuk M, Dresser GK, Hackam DG.

J Transl Int Med. 2017 Jun 30;5(2):93-99. doi: 10.1515/jtim-2017-0020. eCollection 2017 Jun.

8.

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Kline G, Leiter LA, Jones C, Côté AM, Woo V, Kaczorowski J, Trudeau L, Tsuyuki RT, Hiremath S, Drouin D, Lavoie KL, Hamet P, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; Hypertension Canada.

Can J Cardiol. 2017 May;33(5):557-576. doi: 10.1016/j.cjca.2017.03.005. Epub 2017 Mar 10. Erratum in: Can J Cardiol. 2017 Dec;33(12 ):1733-1734.

PMID:
28449828
9.

Coffee-Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine.

Bailey DG, Dresser GK, Urquhart BL, Freeman DJ, Arnold JM.

Am J Hypertens. 2016 Dec 1;29(12):1386-1393. doi: 10.1093/ajh/hpw081.

PMID:
27481881
10.

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; CHEP Guidelines Task Force.

Can J Cardiol. 2016 May;32(5):569-88. doi: 10.1016/j.cjca.2016.02.066. Epub 2016 Mar 10.

PMID:
27118291
11.

Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH).

Lee JJ, Bykerk VP, Dresser GK, Boire G, Haraoui B, Hitchon C, Thorne C, Tin D, Jamal S, Keystone EC, Pope JE.

Clin Med Insights Arthritis Musculoskelet Disord. 2016 Apr 4;9:37-43. doi: 10.4137/CMAMD.S38092. eCollection 2016.

12.

Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel Disease.

Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, Chande N, Mosli M, Kim RB.

J Popul Ther Clin Pharmacol. 2016;23(1):e26-36. Epub 2016 Feb 22.

PMID:
26950049
13.

Overcoming Challenges With Statin Therapy.

Spence JD, Dresser GK.

J Am Heart Assoc. 2016 Jan 27;5(1). pii: e002497. doi: 10.1161/JAHA.115.002497. Review. No abstract available.

14.

Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.

Woolsey SJ, Beaton MD, Choi YH, Dresser GK, Gryn SE, Kim RB, Tirona RG.

Basic Clin Pharmacol Toxicol. 2016 Apr;118(4):284-91. doi: 10.1111/bcpt.12492. Epub 2015 Oct 14.

15.

The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Ramesh Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Brian Penner S, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Stone JA, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Fournier A, Lewanczuk R, Dresser GK, Sharma M, Reid D, Benoit G, Feber J, Harris KC, Poirier L, Padwal RS.

Can J Cardiol. 2015 May;31(5):549-68. doi: 10.1016/j.cjca.2015.02.016. Review.

PMID:
25936483
16.

A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study.

Wijeysundera DN, Choi PT, Badner NH, Brasher PM, Dresser GK, Delgado DH, Beattie WS.

Can J Anaesth. 2014 Nov;61(11):995-1003. doi: 10.1007/s12630-014-0226-6. Epub 2014 Sep 5.

17.

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, Rabkin SW, Trudeau L, Feldman RD, Cloutier L, Prebtani A, Herman RJ, Bacon SL, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Lindsay P, Hill MD, Coutts SB, Gubitz G, Gelfer M, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Burns KD, Petrella RJ, Hiremath S, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Khara M, Pipe A, Oh P, Selby P, Sharma M, Reid DJ, Tobe SW, Padwal RS, Poirier L; Canadian Hypertension Education Program.

Can J Cardiol. 2014 May;30(5):485-501. doi: 10.1016/j.cjca.2014.02.002. Epub 2014 Feb 22. Review.

18.

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB.

Circ Cardiovasc Genet. 2013 Aug;6(4):400-8. doi: 10.1161/CIRCGENETICS.113.000099. Epub 2013 Jul 22.

19.

Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2).

Dresser GK, Nelson SA, Mahon JL, Zou G, Vandervoort MK, Wong CJ, Feagan BG, Feldman RD.

J Hypertens. 2013 Aug;31(8):1702-13. doi: 10.1097/HJH.0b013e3283619d6a.

PMID:
23743804
20.

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS; Canadian Hypertension Education Program.

Can J Cardiol. 2013 May;29(5):528-42. doi: 10.1016/j.cjca.2013.01.005. Epub 2013 Mar 29.

PMID:
23541660
21.

The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE, Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, Honos G, Herman RJ, Schiffrin EL, Bolli P, Wilson T, Feldman RD, Lindsay MP, Hemmelgarn BR, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Lamarre-Cliché M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess E, Lewanczuk R, Dresser GK, Penner B, Hegele RA, McFarlane PA, Sharma M, Campbell NR, Reid D, Poirier L, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2012 May;28(3):270-87. doi: 10.1016/j.cjca.2012.02.018. Review.

PMID:
22595447
22.

Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.

Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB.

Eur Heart J. 2012 Nov;33(22):2856-2464a. doi: 10.1093/eurheartj/ehs042. Epub 2012 Feb 27.

PMID:
22374717
23.

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.

Gong IY, Schwarz UI, Crown N, Dresser GK, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Wells PS, Kim RB, Tirona RG.

PLoS One. 2011;6(11):e27808. doi: 10.1371/journal.pone.0027808. Epub 2011 Nov 16.

24.

The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, Cloutier L, Bolli P, Hill MD, Wilson T, Penner B, Burgess E, Lamarre-Cliché M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NR, Vallée M, Prasad GV, Lebel M, Campbell TS, Lindsay MP, Herman RJ, Larochelle P, Feldman RD, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Lewanczuk R, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Poirier L, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2011 Jul-Aug;27(4):415-433.e1-2. doi: 10.1016/j.cjca.2011.03.015. English, French.

PMID:
21801975
25.

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.

Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, Larue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB.

Blood. 2011 Sep 15;118(11):3163-71. doi: 10.1182/blood-2011-03-345173. Epub 2011 Jul 1.

26.

In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.

Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ.

J Clin Pharmacol. 2012 Apr;52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19.

PMID:
21505084
27.

Influence of noninvasive cardiovascular imaging in primary prevention: systematic review and meta-analysis of randomized trials.

Hackam DG, Shojania KG, Spence JD, Alter DA, Beanlands RS, Dresser GK, Goela A, Davies AH, Badano LP, Poldermans D, Boersma E, Njike VY.

Arch Intern Med. 2011 Jun 13;171(11):977-82. doi: 10.1001/archinternmed.2011.69. Epub 2011 Mar 14. Review.

PMID:
21403010
28.

Barriers to blood pressure control: a STITCH substudy.

Nelson SA, Dresser GK, Vandervoort MK, Wong CJ, Feagan BG, Mahon JL, Feldman RD.

J Clin Hypertens (Greenwich). 2011 Feb;13(2):73-80. doi: 10.1111/j.1751-7176.2010.00392.x. Epub 2010 Dec 10.

29.

New trends in hypertension management: of salt, going solo and single pill combos.

Dresser GK, Feldman RD.

Curr Opin Cardiol. 2010 Jul;25(4):342-9. doi: 10.1097/HCO.0b013e32833a6e09. Review.

PMID:
20520538
30.

The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée M, Prasad GV, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2010 May;26(5):249-58. Review.

31.

Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial.

House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD.

JAMA. 2010 Apr 28;303(16):1603-9. doi: 10.1001/jama.2010.490.

PMID:
20424250
32.

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.

Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB.

Pharmacogenet Genomics. 2008 May;18(5):439-48. doi: 10.1097/FPC.0b013e3282f974dc.

33.

Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.

Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W.

Clin Pharmacol Ther. 2007 May;81(5):669-78. Epub 2007 Mar 28.

PMID:
17392718
34.

Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice.

Bailey DG, Dresser GK, Leake BF, Kim RB.

Clin Pharmacol Ther. 2007 Apr;81(4):495-502. Epub 2007 Feb 14.

PMID:
17301733
35.

Severe necrotizing pancreatitis following combined hepatitis A and B vaccination.

Shlomovitz E, Davies W, Cairns E, Brintnell WC, Goldszmidt M, Dresser GK.

CMAJ. 2007 Jan 30;176(3):339-42.

36.

Acute respiratory failure during pregnancy: a case of nitrofurantoin-induced pneumonitis.

Mohamed A, Dresser GK, Mehta S.

CMAJ. 2007 Jan 30;176(3):319-20. No abstract available.

37.

Intestinal drug transporter expression and the impact of grapefruit juice in humans.

Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB.

Clin Pharmacol Ther. 2007 Mar;81(3):362-70. Epub 2007 Jan 10.

PMID:
17215845
38.
39.

Interactions between grapefruit juice and cardiovascular drugs.

Bailey DG, Dresser GK.

Am J Cardiovasc Drugs. 2004;4(5):281-97. Review.

PMID:
15449971
40.

Natural products and adverse drug interactions.

Bailey DG, Dresser GK.

CMAJ. 2004 May 11;170(10):1531-2. No abstract available.

41.

The effects of fruit juices on drug disposition: a new model for drug interactions.

Dresser GK, Bailey DG.

Eur J Clin Invest. 2003 Nov;33 Suppl 2:10-6. Review.

PMID:
14641551
42.

Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice.

Bailey DG, Dresser GK, Bend JR.

Clin Pharmacol Ther. 2003 Jun;73(6):529-37.

PMID:
12811362
43.

Bioavailability of omega-3 essential fatty acids from perilla seed oil.

Kurowska EM, Dresser GK, Deutsch L, Vachon D, Khalil W.

Prostaglandins Leukot Essent Fatty Acids. 2003 Mar;68(3):207-12.

PMID:
12591004
44.

A basic conceptual and practical overview of interactions with highly prescribed drugs.

Dresser GK, Bailey DG.

Can J Clin Pharmacol. 2002 Winter;9(4):191-8. Review.

PMID:
12584577
45.

Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.

Dresser GK, Schwarz UI, Wilkinson GR, Kim RB.

Clin Pharmacol Ther. 2003 Jan;73(1):41-50.

PMID:
12545142
46.

Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo.

Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG.

Clin Pharmacol Ther. 2002 Sep;72(3):247-55.

PMID:
12235445
47.

Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB.

Clin Pharmacol Ther. 2002 Jan;71(1):11-20.

PMID:
11823753
48.

Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR.

Clin Pharmacol Ther. 2001 Aug;70(2):189-99.

PMID:
11503014
49.

Red wine-cisapride interaction: comparison with grapefruit juice.

Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG.

Clin Pharmacol Ther. 2001 Jul;70(1):17-23.

PMID:
11452240
50.

Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients.

Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR.

Clin Pharmacol Ther. 2000 Nov;68(5):468-77.

PMID:
11103749

Supplemental Content

Loading ...
Support Center